---
title: "Shanghai Kaibao Pharmaceutical Co.,Ltd. (300039.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300039.SZ.md"
symbol: "300039.SZ"
name: "Shanghai Kaibao Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-06-24T16:13:36.832Z"
locales:
  - [en](https://longbridge.com/en/quote/300039.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300039.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300039.SZ.md)
---

# Shanghai Kaibao Pharmaceutical Co.,Ltd. (300039.SZ)

## Company Overview

Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and respiratory infections; and Phlegm-Heat Clearing Capsules to clear heat, resolve phlegm, and detoxifying. It also provides liver-protecting products, including Thiopronine for injection and Thiopronine enteric-coated tablets. In addition, the company provides Astragalus and Ginseng Capsules for the treatment of cardiovascular and cerebrovascular diseases.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.xykb.com](https://www.xykb.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-24T04:30:09.000Z

**Overall: C (0.52)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 140 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -25.97% |  |
| Net Profit YoY | -30.22% |  |
| P/B Ratio | 0.98 |  |
| Dividend Ratio | 2.96% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4602038431.95 |  |
| Revenue | 1037550839.17 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 5.83% | C |
| Profit Margin | 25.03% | A |
| Gross Margin | 80.82% | A |
| Revenue YoY | -25.97% | E |
| Net Profit YoY | -30.22% | D |
| Total Assets YoY | 8.75% | B |
| Net Assets YoY | 11.08% | B |
| Cash Flow Margin | 73.20% | C |
| OCF YoY | -25.97% | E |
| Turnover | 0.21 | D |
| Gearing Ratio | 8.14% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai Kaibao Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-25.97%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-30.22%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.98",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.96%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4602038431.95",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1037550839.17",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "5.83%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "25.03%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "80.82%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-25.97%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-30.22%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "8.75%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "11.08%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "73.20%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-25.97%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.21",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "8.14%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 17.52 | 41/222 | 19.55 | 18.77 | 17.95 |
| PB | 0.97 | 13/222 | 1.53 | 1.46 | 1.36 |
| PS (TTM) | 4.38 | 130/222 | 5.68 | 5.39 | 5.08 |
| Dividend Yield | 3.00% | 42/222 | 2.21% | 2.03% | 1.60% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300039.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300039.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300039.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300039.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**